Even if polygenic embryo screening worked exactly as advertised, it could still do real social damage. That’s the argument from Gaia Ghirardi of the WZB Berlin Social Science Center, Arno Van Hootegem of the Norwegian Institute of Public Health and K. Paige Harden of the University of Texas at Austin in a correspondence published in Nature Human Behaviour.
The technology, known as PGT-P, lets IVF patients rank embryos using polygenic scores, statistical estimates that pool the tiny effects of many genetic variants. The authors set aside whether those predictions work and argue that commercialization itself is the problem.
Their lead concern is “selective pronatalism,” which they define as “policies and discourses that encourage childbearing among specific, allegedly desirable groups.” They contrast it with universal family policies like paid parental leave, built on the premise that “reproduction is a collective good.” They also warn of commodification and a shift in the moral burdens of parenthood, concluding that “PGT-P commercialization presents a new source of stigma and pressure for parents and will widen reproductive inequalities.”
It’s a striking reframe. Earlier critics asked whether polygenic scores deliver. This argument targets the act of choosing itself, recasting a private medical decision as a social harm.
Related on the SLP
Taken to its conclusion, that logic doesn’t stop at IVF. Prenatal testing for severe genetic disorders such as Tay-Sachs or trisomy 13 also lets parents decide which pregnancies continue. If selecting among embryos is a source of “stigma and pressure,” the same charge could be leveled at parents who end a pregnancy after a devastating diagnosis, a decision long seen as theirs to make.
